Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 23, 2024

BUY
$2.16 - $3.66 $229,679 - $389,178
106,333 New
106,333 $313,000
Q3 2023

Nov 14, 2023

BUY
$2.56 - $4.4 $272,212 - $467,865
106,333 New
106,333 $274,000

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $128M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Aristides Capital LLC Portfolio

Follow Aristides Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aristides Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aristides Capital LLC with notifications on news.